Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …

Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …

Cyclin-dependent kinases (CDKs) and their regulators show frequent abnormalities in
tumors. Ten low molecular weight pharmacologic inhibitors of CDKs are currently in clinical …

Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Roscovitine has been reported to have anti-tumor effects in some cancer cell lines. The
phosphatidylinositol-3-kinase (PI3K) signaling, which activates protein kinase B (PKB)/Akt, is …

Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs
in the context of new cancer therapies. Roscovitine and related compounds, like seliciclib …

The phosphorylation state of Retinoblastoma protein (Rb) plays a role in cell proliferation
and apoptosis. Within cells, cyclin dependent kinases (cdks) phosphorylate Rb in response …

We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that
roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin …

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …